Cemiplimab

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

Perspectives on the Science: Ipi/Nivo for Advanced MCC

We provide a commentary on the recent Lancet Oncology article on Ipi/Nivo advanced MCC.

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

Perspectives on the Science: Neoadjuvant Cemiplimab for High-Risk CSCC

We provide a commentary on the recent NEJM article on neoadjuvant cemiplimab for advanced CSCC.

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

We present a prosepective study of neoadjuvant cemiplimab in high-risk resectable CSCC.

Immune Checkpoint Inhibition in Marjolin Ulcer - A Case Series

We provide a case series in the Journal of Immunotherapy of response to anti-PD1 therapy in Marjolin Ulcer.

Real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma

In the JAAD, we provide a real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma.